Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A study published in the Bulletin of the World Health Organization describes a plausible range for the risk of microcephaly in women who were infected with Zika virus during pregnancy compared to those who were not infected.

Image courtesy of Shutterstock

Investigators obtained data on the number of notified and confirmed microcephaly cases in each Brazilian state between November 2015 and October 2016 from the health ministry. For Pernambuco State, one of the hardest hit, weekly data were available from August 2015 to October 2016 for different definitions of microcephaly.

Read more (ISARIC website)

About ISARIC 

ISARIC – the International Sever Acute Respiratory and emerging Infection Consortium – is part of ZIKAlliance, a multinational and multi-disciplinary research consortium comprised of 53 partners worldwide and funded by the European Union's Horizon 2020 Research and Innovation Programme. The consortium focuses on the impact of ZIKV infection during pregnancy and the natural history of ZIKV in humans and their environment. In collaboration with two other EU-funded consortia (ZikaPLAN and ZIKAction), ZIKAlliance is working to develop a preparedness platform in Latin America and the Caribbean. 

ISARIC’s Coordinating Centre - based at the Centre for Tropical Medicine and Global Health in Oxford University's NDM Research Building - is leading on the activities of work package 8 (Communication, Dissemination, and Evaluation), and co-leading work package 11 (ZIKA COLLAB).

Similar stories

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.

Overusing antibiotics? Find out with Antibiotic Footprint Calculator

To help reduce the overuse of antibiotics, Oxford researchers today released a new, easy to use online tool – Antibiotic Footprint Calculator – that could make an important contribution in the fight against antimicrobial resistance (AMR), one of the world’s most significant emerging threats to public health.

$2m fund awarded for Oxford’s single-cell ancestry vaccine research

The University of Oxford is to benefit from $2 million (£1.49 million) in funding from the Chan Zuckerberg Initiative (CZI) to investigate how our ancestry and diversity influence the way that vaccines work in our cells.